Risk factors for an atherothrombotic event in patients with diabetic macular edema treated with intravitreal injections of bevacizumab

作     者：Alon Tiosano Aviel Hadad Noam Yanculovic 

作者机构：Department of OphthalmologySoroka University Medical CenterBen-Gurion University of the NegevBeer Sheva 84101Israel 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2020年第13卷第9期

页      面：1411-1416页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100212[医学-眼科学] 10[医学] 

基　　金：Supported by Department of Ophthalmology at Soroka University Medical Center Research Fund 

主　　题：atherothrombotic event bevacizumab diabetic macular edema 

摘      要：AIM:To identify risk factors for an atherothrombotic event(ATE)among patients who were treated for diabetic macular edema(DME)with intravitreal bevacizumab ***:This retrospective study enrolled all consecutive patients with DME who were treated by intravitreal bevacizumab from 2009 through 2016 in a single *** were divided into one group treated by bevacizumab and subsequently had an ATE and a second group also treated by bevacizumab and did not have an ***:A total of 455 patients with DME were ***-two of the patients had an ATE.A multivariate model adjusted for age,gender,smoking,body mass index,hemoglobin A1c(HbA1c),duration of diabetes,creatinine,and blood pressure revealed an increased risk for ATE in the patients with diabetic duration of more than 13 y,a systolic blood pressure over 153.5 mm Hg at first treatment,or having been treated by more than 4 intravitreal bevacizumab ***,patients that had an ATE within 3 mo from the last intravitreal treatment underwent more bevacizumab injections(5.2±3.4 vs 3.07±1.86;P153.5 mm Hg,a history of diabetic mellitus for more than 13 y,and treatment with more than 4 intravitreal bevacizumab *** factors need to be borne in mind when bevacizumab is being considered in the management of patients with DME.